Plain-English translation of NCT07039110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing how risankizumab, an already-approved medication for psoriasis, affects the daily lives and well-being of adults with moderate-to-severe plaque psoriasis. About 700 people will take this medication exactly as their doctor prescribes it during their regular care. The study will track how the treatment changes their quality of life over up to 2.5 years.
While this medication is already approved and used to treat psoriasis, researchers want to understand how it truly impacts patients' daily activities, emotional well-being, and overall quality of life in real-world clinical practice—not just how it clears the skin.
You likely qualify if…
You likely don't qualify if…
You will take the medication exactly as your doctor prescribes it as part of your normal care—there are no special study procedures or extra burden. You'll attend regular check-in visits at your hospital or clinic over up to 2.5 years, during which researchers will ask you about how the treatment is affecting your daily life, emotional well-being, and activities. These visits will fit into your routine clinical care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada